2
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Trio Medicines Ltd. is a company with 2 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| digestive system neuroendocrine neoplasm | netazepide | Des.TrialAppr. |
| familial adenomatous polyposis 1 | netazepide | Des.TrialAppr. |
| gastric enterochromaffin cell serotonin-producing neuroendocrine tumor | Ceclazepide | Des.TrialAppr. |
| gastric neuroendocrine tumor G1 | Ceclazepidenetazepide | Des.TrialAppr. |
| gastric neuroendocrine tumor G2 | Ceclazepide | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio